Article: Myogen Sinks On Bad News From Enoximone's Phase III.

Article from:
BIOWORLD Today
Article date:
November 3, 2009
Copyright

West Coast Editor

Three months after Myogen Inc.'s lead drug candidate for heart failure, enoximone, missed statistical significance in the primary endpoint of a Phase III trial - an event the company blamed on unexpected improvements in patients given placebo - the compound has failed in top-line results from two more Phase III studies.

William Freytag, president and CEO of Denver-based Myogen, said the company found the most recent data "surprising, given the encouraging results in prior studies" with the drug. He told investors during a conference call that the trials' design was "exemplary," but the oral drug didn't work and the company is giving up ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;  October 22, 1998 ;     700+ words ... ... two European/Canadian Phase III studies in which its ... reported data from other Phase III trials that ended with ... below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along with the Phase III data, the company reported ...

Article: TARGETING A SLICE OF MARKET HELD BY AMGEN TRANSKARYOTIC, HOECHST ...
BIOWORLD Today;  September 30, 1998 ;     700+ words ... ... said Tuesday they began Phase III studies of their gene ... year. The start of the Phase III trial triggered a $2 ... reopened later. (See BioWorld Today, April 17, 1998, p ... The fact they got the Phase III trial going is interesting ...

Article: DRUG FOR CROHN'S DISEASE WORKS ON JOINTS, TOO CENTOCOR'S REMICADE ...
BIOWORLD Today;  November 10, 1998 ;     700+ words ... ... improvements in rheumatoid arthritis (RA) symptoms in a 30-week Phase III trial. Results will form the basis of a new drug application ... diseases that have an inflammation component," Allman told BioWorld Today. Adding RA as an indication "speaks to the infrastructure ...

Article: IN METASTATIC BRAIN CANCER PHARMACYCLICS BEGINS PHASE ...
BIOWORLD Today;  September 28, 1998 ;     700+ words ... ... Friday began a pivotal Phase III trial of its lead product ... years," Ginsberg told BioWorld Today. "Currently, there ... Fast-Track Review The Phase III study will be prospectively ... primary endpoint, the Phase III trial qualifies for ...

Article: SIX-MONTH FOLLOW-UP SUPPORTS EARLIER RESULTS CENTOCOR'S REOPRO ...
BIOWORLD Today;  October 12, 1998 ;     700+ words ... ... marketing to prevent cardiac ischemic complications in a range of patients undergoing percutaneous coronary intervention. (See BioWorld Today, Nov. 7, 1997, p. 1.) "There are a lot of reasons why ReoPro should continue to do well," said Jay Silverman ...

Article: Endovasc Inc. Makes Front Page News in BioWorld ...
Business Wire;  September 2, 2004 ;     700+ words ... ... on Aug. 20, 2004, BioWorld Today, a respected biotech ... clinical trials. In the BioWorld Today article the promising ... Randall Osborne of BioWorld Today, Endovasc details ... growth and financing for Phase III trials. About Endovasc ...

Article: CENTOCOR UNVEILS NEW TARGETS, PLANS A FOCUS ON THERAPEUTICS By ...
BIOWORLD Today;  November 2, 1998 ;     700+ words ... ... Robertson Stephens in New York, told BioWorld Today. "There was a very good feeling ... Individually, ReoPro is in a Phase III trial for unstable angina and in ... party for Centocor," he told BioWorld Today. "We were able to demonstrate ...

Article: MEGABIOS, TARGETED GENETICS PRESENT EARLY CF TRIAL RESULTS By Jim ...
BIOWORLD Today;  October 19, 1998 ;     700+ words ... ... and CFO for Megabios, told BioWorld Today. "We weren't looking for ... including one for the start of Phase III studies - and royalties on sales ... CEO of Targeted Genetics, told BioWorld Today. "Meanwhile, we are gearing ...

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!

Find articles, research, and archives